The 10 largest orthopedic device companies in the world

[Image from Pixaby]

Pent-up demand could make orthopedic devices a hot space in 2021.

The COVID-19 pandemic was especially brutal for the orthopedic device industry. Many of the largest companies in the space saw double-digit percentage declines in revenue in 2020. Health providers delayed or canceled elective procedures to focus on the pandemic, and patients stayed away in droves.

It’s a new year now, though, and vaccines are rolling out. People don’t want to live with a bad knee or hip or back forever. Growth will eventually return for the industry, and orthopedic device companies are positioning themselves to be ready.

Rather than hunkering down during the pandemic, many ortho device companies chose shop for new technologies and major M&A deals. They’re reorganizing and launching new products ranging from surgical robots to smart implants.

Read on and discover the latest about the w…

Read more
  • 0

FDA approves Medtronic’s next-gen Pipeline Flex device with anti-clotting tech

Medtronic (NYSE:MDT) announced today that it received FDA approval for its Pipeline Flex embolization device with Shield Technology.

Fridley, Minn.–based Medtronic’s Shield Technology is a proprietary platform designed to advance flow diversion therapy through a surface-modified implant device that demonstrates a reduction in material thrombogenicity — a reduction in the tendency of the surface treatment material to create clots — according to a news release.

New York City-based NYU Langone Health performed the first patient procedure in the U.S. with the newly cleared Pipeline Flex device with Shield Technology.

Pipeline Flex, which has been on the market for close to 10 years in the U.S., is a device designed to divert blood flow away from a brain aneurysm. A braided, cylindrical mesh tube is implanted across the base or neck of the aneurysm. It interrupts blood flow into the aneurysm and reconstructs the diseased section of the parent vessel. Read more

  • 0

Medtronic touts 2-year study results for In.Pact AV drug-coated balloon

Medtronic (NYSE:MDT) today touted safety and effectiveness results from a 24-month study of its In.Pact AV drug-coated balloon.

Fridley, Minn.-based Medtronic said in a news release that the data demonstrated that the In.Pact AV DCB is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Medtronic blood pump recall is serious

Medtronic Bio Console 560 system (Image from Medtronic)

Medtronic (NYSE: MDT) is recalling a blood pump that can stop during cardiopulmonary bypass surgery due to electrical failure.

The Bio-Console 560 extracorporeal blood pumping console is used to pump and return blood to a person during bypass, a procedure that temporarily takes over the function of the heart and lungs. The cardiopulmonary bypass procedure provides both circulatory and breathing support to a person whose heart and lungs are too weak to pump enough blood to the rest of the body.

Get the full story on our sister site, Medical Design & Outsourcing.

Read more
  • 0

9 medical devices you should keep an eye out for in 2021

The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021.

Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek approval or launch a wide range of new products.

Think surgical robotics, smart orthopedic implants, neurostimulation, single-use scopes and much more.

Here are nine devices to especially keep an eye out for this year.

Next>>
Read more
  • 0

Medtronic has another serious HVAD recall

Medtronic’s HVAD [Image courtesy of Medtronic]The FDA is reporting 12 deaths related to a recall of Medtronic (NYSE:MDT) HeartWare Ventricular Assist Device controller ports.

The recall — which Medtronic initiated on Feb. 26 and FDA designated as Class I — is related to 855 complaints and eight reports of injuries, according to the FDA. Medtronic said today that the FDA’s figures are inaccurate.

The HVAD pump helps the heart continue to pump blood to the rest of the body, providing a bridge to cardiac transplants among people at risk of death from end-stage left ventricular heart failure. HVADs can also support heart tissue recovery and provide a destination therapy when there are no plans for new transplants.

The latest recall involves battery cables, data cables, adapter cables and controller 2.0 ports for HeartWare, according to FDA. Wear and tear of the connector plugs (power sources, data cable, and alarm adapter) can damage the controller …

Read more
  • 0

Medtronic launches 7-day infusion set for diabetes in Europe

[Image from Medtronic]Medtronic (NYSE:MDT) announced today that it launched the Medtronic Extended infusion set for diabetes in select European countries.

Fridley, Minn.–based Medtronic touts the Extended infusion set as the first and only infusion set that a diabetes patient can wear for up to seven days, as most typically infusion pumps that deliver insulin to the body require a set change every few days, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Medtronic has a serious recall of ICDs and CRT-Ds

FDA has issued a Class I designation of a Medtronic (NYSE: MDT) recall involving 239,171 ICDs and CRT-Ds with potential battery life problems.

The agency reported 444 complaints regarding the devices: Evera, Viva, Brava, Claria, Amplia, Compia, and Visia implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-Ds) distributed from Aug. 31, 2012, to May 9, 2018.

Among 264 Medical Device Reports, there were 18 injuries, including people experiencing bradycardia (slow heart rhythm) or heart failure symptoms. There were no reports of deaths.

The devices’ problem involves a potential short circuit that could cause an unexpected and rapid decrease in battery life. The time between the first “Recommended Replacement Time”  warning and full battery depletion could be as little as one day. However, a Medtronic spokesperson noted to MassDevice that the median time from RRT to end of service was 14 days.

Medtronic is no…

Read more
  • 0

AI-aided colon cancer tech gets FDA nod

Cosmo Pharmaceuticals announced today that it received marketing authorization for its GI Genius AI-based lesion detecting system.

GI Genius is an intelligent endoscopy system that uses AI/machine learning to detect lesions in the colon such as polyps or suspected tumors in real-time during a colonoscopy, according to a news release.

The device, which received FDA approval through the de novo pathway, is compatible with all endoscopes. Cosmo is the sole manufacturer, while Medtronic is the exclusive worldwide distributor.

Made up of hardware and software designed to highlight portions of the colon, the device uses AI algorithms to identify regions of interest where it may detect a potential lesion. GI Genius generates markers, which appear as green squares and are accompanied by a short, low-volume sound. It superimposes them on the video from the endoscope camera when a potential lesion is identified.

The device’s signals alert a clinician …

Read more
  • 0

MedTech 100 roundup: Industry roars back

In the blink of an eye, the medtech industry exited its spring slump and neared its all-time best performance levels.

MassDevice‘s MedTech 100 Index offered signs of a rebound last week and has built on that momentum, registering a final tally of 109.39 points on April 9. That represents a 2.9% increase from the 106.26-point mark set a week prior (April 2).

The industry’s rebound has been impressive, given that just over one month prior, the index had dropped to 102.16 points (March 8), having just set its all-time best of 110.96 on Feb. 15. Medtech companies had no seen that degree of a fall since October 2020.

Improvements highlight the secure position the industry has nestled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 18.5% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 76.1% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall …

Read more
  • 0

Medtronic stent graft recall is serious

The FDA has deemed the recall of the Medtronic (NYSE:MDT) Valiant Navion thoracic stent graft system as Class I, the most serious kind.

Medtronic’s Valiant Navion is designed to repair lesions of the descending thoracic aorta, using a long catheter to place the stent graft inside the aorta before it expands to fit within the aorta to provide a new path for blood to flow from the heart to the lower part of the body, according to an FDA release.

Get the full story at our sister site, Medical Tubing & Extrusion.

Read more
  • 0

Medtronic commits to helping people of color with diabetes

Medtronic (NYSE:MDT) announced today that it entered multiple partnerships to help improve health equity for people of color living with diabetes.

Fridley, Minn.-based Medtronic committed investments in partnerships with the American Diabetes Association (ADA) and the T1D Exchange, along with additional research efforts, to better understand and address such disparities, according to a news release.

The company is providing a $1 million sponsorship over the next three years to ADA’s Technology Access Project (TAP) which sets out to provide access and availability of diabetes technology regardless of gender, race, income or location.

“Health equity in diabetes is central to our mission, and unfortunately, for many the latest technological advancements to support living with the disease are not accessible due to insurance barriers and high out-of-pocket costs,” ADA chief development officer Charles D. Henderson said in the release. “…

Read more
  • 0